245 Main Street
Second Floor
Cambridge, MA 02142
United States
617 500 8080
https://immuneering.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 68
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, CEO & Director | 935,09k | N/D | 1983 |
Mr. Robert J. Carpenter M.B.A., M.S. | Co-Founder & Chair Emeritus | 75,36k | N/D | 1946 |
Dr. Brett M. Hall Ph.D. | Chief Scientific Officer | 905,41k | N/D | 1969 |
Mr. Harold E. Brakewood | Chief Business Officer | 579,77k | N/D | 1966 |
Ms. Paula George CPA | Director of Accounting & Operations and Assistant Corporate Controller | N/D | N/D | N/D |
Mr. Michael D. Bookman J.D. | Chief Legal Officer & Secretary | N/D | N/D | 1987 |
Ms. Leah R. Neufeld | Chief People Officer | N/D | N/D | 1973 |
Dr. Peter King Ph.D. | Head of Discovery & VP | N/D | N/D | N/D |
Dr. Praveen Nair Ph.D. | Head of Translational Pharmacology & VP | N/D | N/D | N/D |
Mr. Stephen Sebastian CPA | Executive Director & Corporate Controller | N/D | N/D | N/D |
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
L'ISS Governance QualityScore di Immuneering Corporation al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 6; diritti degli azionisti: 7; retribuzione: 8.